| Cases | Controls |  |  |  |  | ||
---|---|---|---|---|---|---|---|---|
Risk classifier | n | % | n | % | RR1 | 95% CI | RR2 | 95% CI |
Tamoxifen treated (49 cases and 112 controls) | ||||||||
   HOXB13:IL17BR |  |  |  |  |  |  |  |  |
Low risk | 19 | 39% | 58 | 52% | 1.0 | ref | 1.0 | ref |
High risk | 30 | 61% | 54 | 48% | 1.9 | 0.9 - 3.7 | 1.5 | 0.7 - 3.2 |
   MGI |  |  |  |  |  |  |  |  |
Low risk | 12 | 24% | 55 | 49% | 1.0 | ref | 1.0 | ref |
High risk | 37 | 76% | 57 | 51% | 2.9 | 1.3 - 6.2 | 2.1 | 0.8 - 5.5 |
   MGI+HOXB13:IL17BR |  |  |  |  |  |  |  |  |
Low risk | 12 | 24% | 55 | 49% | 1.0 | ref | 1.0 | ref |
Intermediate risk | 14 | 29% | 31 | 28% | 1.8 | 0.7 - 4.8 | 1.3 | 0.4 - 4.2 |
High risk | 23 | 47% | 26 | 23% | 3.5 | 1.5 - 8.1 | 2.7 | 0.9 - 7.5 |
   BCI |  |  |  |  |  |  |  |  |
Low risk | 13 | 27% | 61 | 54% | 1.0 | ref | 1.0 | ref |
Intermediate risk | 15 | 31% | 29 | 26% | 2.2 | 0.9 - 5.6 | 2.1 | 0.8 - 6.0 |
High risk | 21 | 43% | 22 | 20% | 4.2 | 1.7 - 10.3 | 3.3 | 1.1 - 10.3 |
Tamoxifen untreated (90 cases and 174 controls) | ||||||||
   HOXB13:IL17BR |  |  |  |  |  |  |  |  |
Low risk | 41 | 46% | 101 | 58% | 1.0 | ref | 1.0 | ref |
High risk | 49 | 54% | 73 | 42% | 1.6 | 1.0 - 2.7 | 1.3 | 0.8 - 2.3 |
   MGI |  |  |  |  |  |  |  |  |
Low risk | 32 | 36% | 99 | 57% | 1.0 | ref | 1.0 | ref |
High risk | 58 | 64% | 75 | 43% | 2.6 | 1.5 - 4.8 | 1.7 | 0.8 - 3.4 |
   MGI+HOXB13:IL17BR |  |  |  |  |  |  |  |  |
Low risk | 32 | 36% | 99 | 57% | 1.0 | ref | 1.0 | ref |
Intermediate risk | 27 | 30% | 39 | 22% | 2.5 | 1.3 - 4.8 | 1.7 | 0.8 - 3.6 |
High risk | 31 | 34% | 36 | 21% | 2.9 | 1.4 - 5.8 | 1.6 | 0.7 - 3.8 |
   BCI |  |  |  |  |  |  |  |  |
Low risk | 30 | 33% | 108 | 62% | 1.0 | ref | 1.0 | ref |
Intermediate risk | 26 | 29% | 28 | 16% | 3.9 | 1.9 - 8.0 | 3.2 | 1.5 - 6.8 |
High risk | 34 | 38% | 38 | 22% | 3.6 | 1.8 - 7.4 | 2.0 | 0.8 - 4.9 |